Rob Cos has directed his clueless Zombies to buy crmd, ziop and Xon at Much higher levels. Prayers should be directed to those poor hapless investors who bought into his endless hype. In remains to be seen if any of those 3 companies will ever come back to the price he pumped them at:
crmd @ 8+..buyout at 20+ coming.......ziop @ 10+...kirk ready to announce big deal......xon @ 42+...deals and major announcement on biofuel.
Rob is a disgrace .
Some really good synergies between fpmi and GFP. If CEO can pull this off, this newly formed company could attract some serious attention by the big players. FPMI will need additional cash, even thought this is a stock deal, to get this done. Can he do it?
Brew, I have been here for over a decade, and I can say in that time, rgrx never had any cc with biogen. That must have been a long time ago.
Lots of long timers here. Does anyone else remember such a call? I could be wrong, memory aint what it used to be.
I agree with CC. Ground Floor seems like a well run company that has some recent grants and a relationship with Mass General. I don't think Ground Floor would be taking all that stock from FPMI if they didn't believe it would trade much higher. I hope we can close this deal
Well, good enough for Ground Floor to own fpmi, good enough for me. Time to add and average in.
Yes, and that volume is the key there. Gtree is now almost back to where it was trading before the trial news. Expect rgrx to do the same.
What are these criminals doing running this company? How many times has Ma lied to shareholders? He lied about eecp, he lied about "accretive" china acquisitions, and recently lied about communicating more with shareholders.
And Castle has also promised better communication between CCs. But nothing. Stock does no volume and hangs on the lows since castle stole vaso shareholders money with the Netwolfs purchase. Its the perfect scenario for them; keep stock low and under the radar and rape the cash flow of the company by taking huge salaries and bonuses. These guys should all be going to jail.
That was citadel, the recent heavy buyer(started at .38). So, why would they show some size on the offer and then disappear after being a big buyer. Well, if you wanted a lot more shares but didn't want to continue to pay up in an illiquid stock, you might spoof some shares(show big offer without any intention of selling) to get retail here to sell into bid. And maybe get some shares in the hi 40's. So they show size but no one sells, so they pull offer to play another day.
The real question is why is someone going to all this trouble to acquire shares in this little company? We should find out soon enough................
PACB will be bought by Roche. Trading here reminds me of the way Igen traded during its long fight with roche. Roche wanted to buy, but didn't like igen's Ceo demanding top dollar. So, they manipulated Igen's stock lower to put pressure on igen to acquiesce. This is not a rumor, it was a fact presented and proved in court documents. The legal fight went on for years, but igen won and roche ended up paying the top dollar they hoped to avoid. Roche learned a lesson here, but still is a very tough negotiator.
The nonsensical trading pattern up and down and call action(paying 20 cents for those way OTM 12 1/2 calls) say bid will come, but it wont be an easy hold in the meantime. Roche will make sure of that.
Stay long, when you least expect it, deal will be announced. Sooner than later...........imho
Some who took advantage of recent selloff now find that buys in the .3 and .2's are looking very good. Conversely, panic selling by some longs who misunderstood the data aint looking so good. Large recent purchases by Citadel point to even higher prices and imply some positive news; and there could be plenty.
The Novartis news in China and their failed attempts in the past in the dry eye market, while agn and shire advance, may imply some kind of alliance with rgrx near term. And ANY news that has a large pharma or biotech involved will give instant cred to rgrx and much higher prices. The valuations of lifitegrast and visomitin certainly could support a 100+ market cap here.
This is the first of many important partnerships which we anticipate during the course of our clinical development," added Dr. Tulip. "The ongoing advance of CVD and the need for better and more efficient solutions in healthcare worldwide give us increased confidence in the inherent value of our portfolio, and our ability to deliver shareholder value as well."
Hey rob cos, nice job getting me banned from your IV message board. And my only crime was pointing out your revisionist history as to the content and timing of your many failed stock recommendations (crmd, ziop, xon). I should have expected that, given your relationship with the IV owner. I guess that little vegas trip you gave him has really paid off. He lets you kick out all contrary views and run site as your private message board. How legal is that, I wonder?
I don't know if ziop will be a success or not. But I do know your are a charlatan who endlessly hypes and promotes himself at the expense of the unsuspecting investor. What a shame you are allowed to post anywhere.
If you keep repeating the same useless info, do you think it will be any more meaning?
The real money here is to the upside, as there is far more room to move higher on a 50 cent stock than lower. If you had the the intelligence to compare value of rgrx to just mentioned ebio or lifitegrast or visomitin, you might see why price here is so attractive.
But, you were a dope on the scln board and now appear to want to repeat your act here.
And check out the trading in EBIO today. Market cap up 15 mil because the dry eye drug which failed p3 is now seen to not be dead because a genetic testing firm says they have found a small subset of patients in the dry eye group which may respond to EBIO's drug. Talk about data mining.
But it does show the value of dry eye drugs. RGRX is seriously undervalued here compared to everything out there. EBIO is just the latest example and gives all a small idea about how quickly market cap here can change when just a little bit of good news hits.
The question of value here is simple; can rgrx get the FDA to sign on to some very achievable endpoints based on previous trial results? So, here is a great current example of how relaxed endpoints can be.
EBIO started a trial in 600 patients for dry eye which finished in 2015. The results were a total flop: no better than the placebo. But check out the primary endpoints they got:
- NEI score for Total Corneal Fluorescein Staining (TCFS) [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
To evaluate the efficacy of EBI-005 5 mg/mL topical ophthalmic solution given three times daily for 12 weeks as measured by the change in the NEI score for the Total Corneal Fluorescein Staining [sign] from baseline to Week 12 and a change in ocular pain as measured by the painful or sore eye question on the OSDI [symptom] of DED from baseline to Week 12 as compared to vehicle control.
So, for the healing endpoint they got just total staining for 3 months( NO CAE) and for ocular discomfort, get this, they just needed a positive response to 1 question on the OSDI. The total score for the OSDI questionaire was relegated to a secondary endpoint.
And EBIO still has a market cap of around 35 million.
They are still trying to buy on the bid, hoping that a silly retail penny trader might give them some cheap shares. They had no luck with size, so they are playing a little more coy by following bid higher. They have bought very little.
Gtree has now recovered most of what they lost after trial result: they are down about 10%. Nice volume buying there at the start of trading yesterday. We are still off about 40% from trial. I would guess that loss would have been cut in half if not for some "pro" traders here getting emotional and selling for a couple pennies. Citadel and others know value here and trying to buy, but they may have to step up to the offer. Problem for them is that no real size on offer, so they would push stock up too much, so they remain patient. Such is the problem trying to accumulate size in this type of stock.